Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results Mar 30, 2026
Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure Jan 20, 2026
Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting Sep 15, 2025
Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk Apr 24, 2025
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results Jan 31, 2025
PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan Jan 27, 2025
